Telomir Pharmaceuticals, Inc. (TELO)
NASDAQ: TELO · Real-Time Price · USD
1.450
+0.030 (2.11%)
At close: Apr 28, 2026, 4:00 PM EDT
1.470
+0.020 (1.38%)
Pre-market: Apr 29, 2026, 5:41 AM EDT

Telomir Pharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-10.41-16.53-13.07-0.85-0.14
Other Amortization
-4.341.61--
Stock-Based Compensation
6.136.87---
Other Operating Activities
--7.49--
Change in Accounts Payable
-0.050.180.110.390.02
Change in Other Net Operating Assets
0.65-0.06-0--
Operating Cash Flow
-3.69-5.07-3.86-0.47-0.12
Short-Term Debt Issued
0.16-3.120.460.12
Total Debt Issued
0.16-3.120.460.12
Short-Term Debt Repaid
--0.1---
Total Debt Repaid
--0.1---
Net Debt Issued (Repaid)
0.16-0.13.120.460.12
Issuance of Common Stock
9.556.8710.06-
Other Financing Activities
--0.43-0.26-0.05-
Financing Cash Flow
9.716.343.860.470.12
Net Cash Flow
6.021.26-00-
Levered Free Cash Flow
-0.091.1-1.96--
Unlevered Free Cash Flow
-0.09-0.53-2.55--
Change in Working Capital
0.590.130.110.390.02
Source: S&P Capital IQ. Standard template. Financial Sources.